Alveolar rhabdomyosarcoma
MONDO:0009994A rapidly growing malignant mesenchymal neoplasm. It is characterized by the presence of round cells with myoblastic differentiation and a fibrovascular stroma resembling an alveolar growth pattern. The tumor usually presents in the extremities.
Also known as: ARMS, alveolar rhabdomyosarcoma, alveolar rhabdomyosarcoma (disease), alveolar rhabdomyosarcoma (morphologic abnormality), arms, monomorphous round cell rhabdomyosarcoma, paediatric alveolar rhabdomyosarcoma, pediatric alveolar rhabdomyosarcoma
2833 clinical trials for this condition and its sub-types, 9 tagged with Alveolar rhabdomyosarcoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
Could adding temsirolimus boost chemo for childhood muscle cancer?
Disease control OngoingThis phase 3 trial tests whether adding the drug temsirolimus to standard chemotherapy helps children and young adults with intermediate-risk rhabdomyosarcoma, a type of muscle cancer. About 325 participants receive either standard chemo or standard chemo plus temsirolimus. The s…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New drug cocktail shows promise against aggressive childhood cancer
Disease control OngoingThis study tests whether adding a drug called vinorelbine to standard chemotherapy can better control high-risk rhabdomyosarcoma, a rare and aggressive muscle cancer in children and young adults. About 118 participants will receive either the standard treatment or the new combina…
Phase 3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New hope for kids with tough cancers: elimusertib trial launches
Disease control OngoingThis study tests a drug called elimusertib in children and young adults (ages 1 to 30) whose solid tumors have returned or not responded to treatment. The drug works by blocking an enzyme that cancer cells need to grow. The trial aims to find the safest dose and see if the drug c…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New chemo timing strategies aim to outsmart aggressive childhood cancer
Disease control OngoingThis study tests four different chemotherapy schedules in children and adults with a rare, aggressive muscle cancer that has spread. Participants choose from a first-strike approach, a first-strike followed by maintenance, an adaptive schedule, or standard chemo. The goal is to s…
Phase 2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Gene hunt: could DNA secrets unlock rhabdomyosarcoma prognosis?
Knowledge-focused OngoingThis study explores genetic mutations in children with embryonal or alveolar rhabdomyosarcoma by analyzing saliva or cheek cell samples from the child and their parents. The goal is to identify inherited or new gene changes that may help doctors predict how the disease will progr…
Sponsor: Children's Oncology Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC